Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923921 · ClinicalTrials.gov registry record · Phase 3
Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 567
- Enrollment target
NCT02923921 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 567 participants.
The verdict
NCT02923921, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 567 participants
- Enrollment target
Study Summary
To compare the efficacy of pegilodecakin in combination with FOLFOX versus FOLFOX alone in participants with metastatic pancreatic cancer as measured by overall survival.
Interventions
- DRUG FOLFOX
- BIOLOGICAL Pegilodecakin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 567 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2020-03-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02923921
The ClinicalTrials.gov registry entry for NCT02923921 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 567 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FOLFOX is the first listed.
NCT02923921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02923921 about?
NCT02923921 is a clinical study titled "Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer". To compare the efficacy of pegilodecakin in combination with FOLFOX versus FOLFOX alone in participants with metastatic pancreatic cancer as measured by overall survival.
What is the current status of trial NCT02923921?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 567 participants. The study started on 2017-03-01. Estimated completion is 2020-03-05.
What interventions are being tested in trial NCT02923921?
The interventions under investigation include: FOLFOX (DRUG), Pegilodecakin (BIOLOGICAL).
Who is sponsoring clinical trial NCT02923921?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.